MedPath

Evaluation of the Efficacy of Surfaktant in Preterm Infants by Lung Ultrasound

Not Applicable
Conditions
Lung Ultrasound Scores
Registration Number
NCT03655457
Lead Sponsor
Zekai Tahir Burak Women's Health Research and Education Hospital
Brief Summary

To compare the lung ultrasound scores after two different natural surfactant administration as a parameter reflecting lung inflation. Poractant alfa decreases lung ultrasound scores as efficient as beractant treatment

Detailed Description

Outcomes:

Improvement of Lung usg scores after surfactanct and the difference between groups at different time points (2nd and 6hr).

Secondary outcome:

The correlation between lung usg scores and clinical scores (silverman scores), FiO2 and PCO2 levels, failure of weaning to noninvasive ventilation after surfactant Preterm infants of 32 gestational weeks and below, who admit to the NICU with signs of respiratory distress, treated with non invasive or mechanical ventilation and require surfactant treatment in 6 hours of life will be enrolled.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
64
Inclusion Criteria
  • Preterm infants of 32 gestational weeks and below, who admit to the NICU with signs of respiratory distress, treated with non invasive or mechanical ventilation and require surfactant treatment in 6 hours of life will be enrolled.
Exclusion Criteria
  • major congenital anomalies.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Lung usg scoresfirst days

Evaluation of Lung Usg Scores in infants treated with surfactant in the first six hours (Brat lung usg scores). Each item scored 0-3. (0 indicates A-pattern (defined by the presence of the only A-lines); 1, B-pattern (defined as the presence of ≥3 well-spaced B-lines); 2, severe B-pattern (defined as the presence of crowded and coalescent B-lines with or without consolidations limited to the subpleural space); and 3, extended consolidations.)

- Higher values represent a worse outcome

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Zekai Tahir Burak Matarnity Teaching

🇹🇷

Ankara, Turkey

Zekai Tahir Burak Matarnity Teaching
🇹🇷Ankara, Turkey
Davut Bozkaya, MD
Contact
+905053197531
drbozkaya@gmail.com
Şebnem Özyer, MD
Contact
+903123065272
sebnemsenozyer@yahoo.com,

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.